NAMS vs. VKTX

Last updated Jun 23, 2026

NAMS (NewAmsterdam Pharma Company N.V.) and VKTX (Viking Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, NAMS returned 36.19%/yr vs 16.64%/yr for VKTX. At a 0.23 correlation, their price movements are largely independent.

Performance

NAMS vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in NewAmsterdam Pharma Company N.V. (NAMS) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NAMS achieves a -12.14% return, which is significantly lower than VKTX's -7.99% return.

NAMS

• 1D: 3.32%
• 1M: -13.04%
• YTD: -12.14%
• 6M: -15.54%
• 1Y: 71.60%
• 3Y*: 36.19%
• 5Y*: —
• 10Y*: —

VKTX

• 1D: 6.55%
• 1M: 4.79%
• YTD: -7.99%
• 6M: -8.56%
• 1Y: 24.45%
• 3Y*: 16.64%
• 5Y*: 39.58%
• 10Y*: 38.57%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NAMS vs. VKTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
NAMS NewAmsterdam Pharma Company N.V.	-12.14%	36.50%	130.08%	2.48%	-0.91%
VKTX Viking Therapeutics, Inc.	-7.99%	-12.57%	116.23%	97.98%	131.53%

Correlation

The correlation between NAMS and VKTX is 0.47, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.47
Correlation (3Y) Calculated over the trailing 3-year period	0.30
Correlation (All Time) Calculated using the full available price history since Nov 23, 2022	0.23

Over the past year, NAMS and VKTX have become more correlated (0.47) than their long-term average of 0.23, meaning their price movements have been converging.

Fundamentals

EPS NAMS : -$1.90 VKTX : -$4.16
Total Revenue (TTM) NAMS : $22.57M VKTX : $0.00
Gross Profit (TTM) NAMS : $19.47M VKTX : -$208.00K
EBITDA (TTM) NAMS : -$173.45M VKTX : -$501.77M

Return for Risk

NAMS vs. VKTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NAMS

NAMS Risk / Return Rank: 76
NAMS Sharpe Ratio Rank: 78
NAMS Sortino Ratio Rank: 76
NAMS Omega Ratio Rank: 71
NAMS Calmar Ratio Rank: 78
NAMS Martin Ratio Rank: 74

VKTX

VKTX Risk / Return Rank: 55
VKTX Sharpe Ratio Rank: 54
VKTX Sortino Ratio Rank: 54
VKTX Omega Ratio Rank: 58
VKTX Calmar Ratio Rank: 54
VKTX Martin Ratio Rank: 54

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NAMS vs. VKTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for NewAmsterdam Pharma Company N.V. (NAMS) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	NAMS	VKTX	Difference
Sharpe ratio: Return per unit of total volatility	1.27	0.33	+0.94
Sortino ratio: Return per unit of downside risk	1.99	0.94	+1.05
Omega ratio: Gain probability vs. loss probability	1.23	1.15	+0.08
Calmar ratio: Return relative to maximum drawdown	2.29	0.54	+1.75
Martin ratio: Return relative to average drawdown	4.53	1.06	+3.48

NAMS vs. VKTX - Sharpe Ratio Comparison

The current NAMS Sharpe Ratio is 1.27, which is higher than the VKTX Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of NAMS and VKTX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

NAMS vs. VKTX - Drawdown Comparison

The maximum NAMS drawdown since its inception was -66.23%, smaller than the maximum VKTX drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for NAMS and VKTX.

Drawdown Indicators

	NAMS	VKTX	Difference
Max Drawdown Largest peak-to-trough decline	-66.23%	-90.41%	+24.18%
Max Drawdown (1Y) Largest decline over 1 year	-31.41%	-45.14%	+13.73%
Max Drawdown (3Y) Largest decline over 3 years	-50.98%	-78.86%	+27.88%
Max Drawdown (5Y) Largest decline over 5 years	—	-78.86%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-89.26%	—
Current Drawdown Current decline from peak	-25.65%	-65.75%	+40.10%
Average Drawdown Average peak-to-trough decline	-22.13%	-60.02%	+37.89%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.84%	23.15%	-7.31%

Volatility

NAMS vs. VKTX - Volatility Comparison

The current volatility for NewAmsterdam Pharma Company N.V. (NAMS) is 11.44%, while Viking Therapeutics, Inc. (VKTX) has a volatility of 14.91%. This indicates that NAMS experiences smaller price fluctuations and is considered to be less risky than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NAMS	VKTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	11.44%	14.91%	-3.47%
Volatility (6M) Calculated over the trailing 6-month period	38.00%	41.26%	-3.26%
Volatility (1Y) Calculated over the trailing 1-year period	56.61%	73.84%	-17.23%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.12%	101.64%	-30.52%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.12%	97.04%	-25.92%

Dividends

NAMS vs. VKTX - Dividend Comparison

Neither NAMS nor VKTX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both NAMS and VKTX in my portfolio?

NAMS and VKTX have a correlation of 0.47, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NAMS or VKTX?

VKTX has higher volatility (14.91%) compared to NAMS (11.44%). In terms of maximum drawdown, NAMS dropped -66.23% vs VKTX's -90.41%.

Which has better risk-adjusted returns?

NAMS currently has the higher Sharpe Ratio (1.27 vs 0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.